PCN226 THE COST-EFFECTIVENESS AND RELAPSE-REDUCTION BENEFIT OF INTRODUCING ADJUVANT NIVOLUMAB FOR PATIENTS WITH COMPLETELY WITH RESECTED MELANOMA WITH LYMPH NODE INVOLVEMENT OR METASTATIC DISEASE IN THE UK
Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.422
https://www.valueinhealthjournal.com/article/S1098-3015(19)32800-1/fulltext
Title :
PCN226 THE COST-EFFECTIVENESS AND RELAPSE-REDUCTION BENEFIT OF INTRODUCING ADJUVANT NIVOLUMAB FOR PATIENTS WITH COMPLETELY WITH RESECTED MELANOMA WITH LYMPH NODE INVOLVEMENT OR METASTATIC DISEASE IN THE UK
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)32800-1&doi=10.1016/j.jval.2019.09.422
First page :
Section Title :
Open access? :
No
Section Order :
10351